<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462030</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00099590</org_study_id>
    <nct_id>NCT03462030</nct_id>
  </id_info>
  <brief_title>Baked Milk Oral Immunotherapy for Cow's Milk Allergy</brief_title>
  <official_title>Phase I Study of Baked Milk Oral Immunotherapy for the Treatment of Cow's Milk Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myra Reinhardt Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>La Jolla Institute for Allergy &amp; Immunology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether baked milk oral immunotherapy is safe in
      the treatment of cow's milk allergy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess the safety of baked milk oral immunotherapy among patients
      who are milk allergic and who do not pass a baked milk challenge.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>End of year 1</time_frame>
    <description>Adverse events will be recorded per CTCAE version 4.0. Events per dose on baked milk oral immunotherapy will be compared to adverse events per dose on placebo. Data will be collected over the first year of treatment. Analysis of cumulative adverse reactions per dose of oral immunotherapy or placebo will be performed at the end of year 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the proportion of subjects who are able to tolerate 4 grams of baked milk protein after one and two years of treatment</measure>
    <time_frame>End of study year 1 and the end of study year 2</time_frame>
    <description>The investigators will perform baked milk challenges to 4044 mg of baked milk protein and calculate the proportion of subjects who tolerate 4 grams of unheated milk protein after one and two years of baked milk oral immunotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cow's Milk Allergy</condition>
  <arm_group>
    <arm_group_label>Baked Milk Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baked non-fat cow's milk powder</intervention_name>
    <description>Oral immunotherapy with increasing quantities of baked milk.</description>
    <arm_group_label>Baked Milk Immunotherapy</arm_group_label>
    <other_name>Investigational New Drug (IND) 17114</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: Tapioca Powder</intervention_name>
    <description>Placebo control.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet all of the following criteria are eligible for enrollment as study
             participants, including participants who:

               -  Are age 3-18 years, either sex, any ethnicity or race

               -  Provide signed informed consent by parent or legal guardian and informed assent
                  if applicable

               -  Have a history of symptomatic reactivity to cow's milk (i.e. eczema, urticarial,
                  upper or lower respiratory symptoms, gastrointestinal disturbances, rash, oral
                  symptoms)

               -  Have a skin prick test positive to milk (diameter of wheal 3 mm ≥ negative
                  control) and serum milk-specific immunoglobulin E (IgE) level &gt;5 kiloUnits (kU)/L
                  within the past 6-12 months

               -  Have a positive reaction to a cumulative dose of ≤444 mg of baked milk powder in
                  the initial qualifying double blind placebo-controlled food challenge.

               -  Use an effective method of contraception by females of childbearing potential to
                  prevent pregnancy and agree to continue to practice an acceptable method of
                  contraception for the duration of their participation in the study.

               -  Have self-injectable epinephrine available at all times

        Exclusion Criteria:

          -  Patients who meet any of these criteria are not eligible for enrollment as study
             participants, including participants who:

               -  Have a history of severe anaphylaxis resulting in hypotension, neurological
                  compromise, or mechanical ventilation

               -  Have a history of intubation related to asthma

               -  Tolerate more than 444 mg of baked milk powder at the initial qualifying double
                  blind placebo controlled food challenge.

               -  Allergy to placebo ingredients or reacts to any dose of placebo during the
                  qualifying oral food challenge.

               -  Poor control of atopic dermatitis

               -  Are unable to tolerate at least 3 mg of baked milk protein on dose escalation day

               -  Are pregnant or lactating

               -  Have severe asthma defined by 2007 National Heart Lung and Blood Institute
                  (NHLBI) Criteria Steps 5 or 6

               -  Have severe or poorly controlled asthma defined by with any of the following
                  criteria:

                    1. Forced expiratory volume in 1 second (FEV1) &lt;80% of predicted

                    2. Inhaled corticosteroid dosing dosing of &gt;500 mcg daily of fluticasone (or
                       equivalent inhaled corticosteroids based on NHLBI dosing chart) or

                    3. ≥ 1 hospitalization in the past year for asthma or

                    4. &gt; 1 emergency department visit in the past 6 months for asthma

               -  Use of steroid medications (oral steroids, such as prednisone or Medrol, steroid
                  injections, such as Kenalog, or intravenous or oral corticosteroid burst) in the
                  following manners: History of daily oral steroid dosing within 4 weeks prior to
                  baseline visit or for &gt; 1 month during the past year or &gt;2 burst oral steroid
                  courses in the past 6 months.

               -  Are unable to discontinue antihistamines for 5 days for long acting and 3 days
                  for short acting prior to skin testing or food challenges

               -  Are receiving omalizumab, mepolizumab, beta- blocker,
                  angiotensin-converting-enzyme inhibitor (ACE-I), angiotensin-receptor blockers,
                  calcium channel blockers, or tricyclic antidepressant therapy

               -  Have used immunomodulatory therapy (not including corticosteroids) or biologic
                  therapy within the past year

               -  Have participated in any interventional study for treatment of a food allergy in
                  the past 6 months

               -  Are on 'build up phase' of environmental allergen immunotherapy. Subjects
                  tolerating maintenance allergen immunotherapy can be enrolled.

               -  Have a history of eosinophilic esophagitis in the past 3 years

               -  Have a chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring
                  therapy (e.g., heart disease, diabetes)

               -  Have used an investigational drug within 90 days or plan to use an
                  investigational drug during the study period

               -  Severe reaction at initial double blind placebo controlled food challenge,
                  defined as:

                    -  Life-threatening anaphylaxis

                    -  Requiring overnight hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C, Camargo CA Jr, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011 Jan;31(1):61-75. doi: 10.1016/j.nutres.2011.01.001.</citation>
    <PMID>21310308</PMID>
  </reference>
  <reference>
    <citation>Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, Holl JL. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20.</citation>
    <PMID>21690110</PMID>
  </reference>
  <reference>
    <citation>Chafen JJ, Newberry SJ, Riedl MA, Bravata DM, Maglione M, Suttorp MJ, Sundaram V, Paige NM, Towfigh A, Hulley BJ, Shekelle PG. Diagnosing and managing common food allergies: a systematic review. JAMA. 2010 May 12;303(18):1848-56. doi: 10.1001/jama.2010.582. Review.</citation>
    <PMID>20460624</PMID>
  </reference>
  <reference>
    <citation>Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014 Feb;133(2):291-307; quiz 308. doi: 10.1016/j.jaci.2013.11.020. Epub 2013 Dec 31. Review.</citation>
    <PMID>24388012</PMID>
  </reference>
  <reference>
    <citation>Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol. 2007 Nov;120(5):1172-7. Epub 2007 Nov 1.</citation>
    <PMID>17935766</PMID>
  </reference>
  <reference>
    <citation>Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, Henning AK, Mayer L, Burks AW, Grishin A, Stablein D, Sampson HA. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol. 2013 Mar;131(3):805-12. doi: 10.1016/j.jaci.2012.10.060. Epub 2012 Dec 28.</citation>
    <PMID>23273958</PMID>
  </reference>
  <reference>
    <citation>Kim J, Kwon J, Noh G, Lee SS. The effects of elimination diet on nutritional status in subjects with atopic dermatitis. Nutr Res Pract. 2013 Dec;7(6):488-94. doi: 10.4162/nrp.2013.7.6.488. Epub 2013 Nov 29.</citation>
    <PMID>24353835</PMID>
  </reference>
  <reference>
    <citation>Hobbs CB, Skinner AC, Burks AW, Vickery BP. Food allergies affect growth in children. J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):133-4.e1. doi: 10.1016/j.jaip.2014.11.004. Epub 2014 Nov 25.</citation>
    <PMID>25577638</PMID>
  </reference>
  <reference>
    <citation>Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010 Aug;65(8):933-45. doi: 10.1111/j.1398-9995.2010.02342.x. Epub 2010 Feb 22. Review.</citation>
    <PMID>20180792</PMID>
  </reference>
  <reference>
    <citation>Flokstra-de Blok BM, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H, DunnGalvin A, Hourihane JO, Duiverman EJ. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010 Feb;65(2):238-44. doi: 10.1111/j.1398-9995.2009.02121.x. Epub 2009 Oct 1.</citation>
    <PMID>19796214</PMID>
  </reference>
  <reference>
    <citation>Eigenmann PA, Caubet JC, Zamora SA. Continuing food-avoidance diets after negative food challenges. Pediatr Allergy Immunol. 2006 Dec;17(8):601-5.</citation>
    <PMID>17121588</PMID>
  </reference>
  <reference>
    <citation>Burbank AJ, Sood P, Vickery BP, Wood RA. Oral Immunotherapy for Food Allergy. Immunol Allergy Clin North Am. 2016 Feb;36(1):55-69. doi: 10.1016/j.iac.2015.08.007. Review.</citation>
    <PMID>26617227</PMID>
  </reference>
  <reference>
    <citation>Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S, Wanich N, Sampson HA. Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol. 2008 Aug;122(2):342-7, 347.e1-2. doi: 10.1016/j.jaci.2008.05.043. Epub 2008 Jul 11.</citation>
    <PMID>18620743</PMID>
  </reference>
  <reference>
    <citation>Kim JS, Nowak-Węgrzyn A, Sicherer SH, Noone S, Moshier EL, Sampson HA. Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol. 2011 Jul;128(1):125-131.e2. doi: 10.1016/j.jaci.2011.04.036. Epub 2011 May 23.</citation>
    <PMID>21601913</PMID>
  </reference>
  <reference>
    <citation>Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992 Aug;90(2):256-62.</citation>
    <PMID>1500630</PMID>
  </reference>
  <reference>
    <citation>Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):744-51.</citation>
    <PMID>9215240</PMID>
  </reference>
  <reference>
    <citation>Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009 Aug;124(2):286-91, 291.e1-6. doi: 10.1016/j.jaci.2009.03.045. Epub 2009 May 27.</citation>
    <PMID>19477496</PMID>
  </reference>
  <reference>
    <citation>Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012 Feb;129(2):448-55, 455.e1-5. doi: 10.1016/j.jaci.2011.10.023. Epub 2011 Nov 30.</citation>
    <PMID>22130425</PMID>
  </reference>
  <reference>
    <citation>Martorell A, De la Hoz B, Ibáñez MD, Bone J, Terrados MS, Michavila A, Plaza AM, Alonso E, Garde J, Nevot S, Echeverria L, Santana C, Cerdá JC, Escudero C, Guallar I, Piquer M, Zapatero L, Ferré L, Bracamonte T, Muriel A, Martínez MI, Félix R. Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy. Clin Exp Allergy. 2011 Sep;41(9):1297-304. doi: 10.1111/j.1365-2222.2011.03749.x. Epub 2011 Apr 11.</citation>
    <PMID>21481024</PMID>
  </reference>
  <reference>
    <citation>Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004 Sep;59(9):980-7.</citation>
    <PMID>15291907</PMID>
  </reference>
  <reference>
    <citation>Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, Ventura A. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008 Feb;121(2):343-7. Epub 2007 Dec 26.</citation>
    <PMID>18158176</PMID>
  </reference>
  <reference>
    <citation>Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008 Dec;122(6):1154-60. doi: 10.1016/j.jaci.2008.09.030. Epub 2008 Oct 25.</citation>
    <PMID>18951617</PMID>
  </reference>
  <reference>
    <citation>Narisety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW, Wood RA. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. J Allergy Clin Immunol. 2009 Sep;124(3):610-2. doi: 10.1016/j.jaci.2009.06.025. Epub 2009 Aug 8.</citation>
    <PMID>19665770</PMID>
  </reference>
  <reference>
    <citation>Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, Passalacqua G. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010 Nov;105(5):376-81. doi: 10.1016/j.anai.2010.03.015. Epub 2010 Jul 31.</citation>
    <PMID>21055664</PMID>
  </reference>
  <reference>
    <citation>Yeung JP, Kloda LA, McDevitt J, Ben-Shoshan M, Alizadehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012 Nov 14;11:CD009542. doi: 10.1002/14651858.CD009542.pub2. Review.</citation>
    <PMID>23152278</PMID>
  </reference>
  <reference>
    <citation>Wood RA. Food allergen immunotherapy: Current status and prospects for the future. J Allergy Clin Immunol. 2016 Apr;137(4):973-982. doi: 10.1016/j.jaci.2016.01.001. Review.</citation>
    <PMID>27059725</PMID>
  </reference>
  <reference>
    <citation>Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, Plaut M, Sampson HA. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol. 2016 Apr;137(4):1103-1110.e11. doi: 10.1016/j.jaci.2015.10.005. Epub 2015 Nov 12.</citation>
    <PMID>26581915</PMID>
  </reference>
  <reference>
    <citation>Goldberg MR, Nachshon L, Appel MY, Elizur A, Levy MB, Eisenberg E, Sampson HA, Katz Y. Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015 Dec;136(6):1601-1606. doi: 10.1016/j.jaci.2015.05.040. Epub 2015 Jul 17.</citation>
    <PMID>26194541</PMID>
  </reference>
  <reference>
    <citation>Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993 Dec;71(6):557-62.</citation>
    <PMID>8267250</PMID>
  </reference>
  <reference>
    <citation>Devenney I, Fälth-Magnusson K. Skin prick tests may give generalized allergic reactions in infants. Ann Allergy Asthma Immunol. 2000 Dec;85(6 Pt 1):457-60.</citation>
    <PMID>11152165</PMID>
  </reference>
  <reference>
    <citation>Valyasevi MA, Maddox DE, Li JT. Systemic reactions to allergy skin tests. Ann Allergy Asthma Immunol. 1999 Aug;83(2):132-6.</citation>
    <PMID>10480586</PMID>
  </reference>
  <reference>
    <citation>Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004 Jun;113(6):1129-36.</citation>
    <PMID>15208595</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food allergy</keyword>
  <keyword>oral immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

